Neoadjuvant hormonal therapy possibilities in breast cancer

04/2019

MUDr. Lucie Reifová

Ústav radiační onkologie Nemocnice Na Bulovce, Praha

SUMMARY

Hormonal therapy is an integral part of a multidisciplinary approach to the treatment of breast cancer with positive estrogen and/or progesteron receptors. While neoadjuvant chemotherapy is well established as a part of therapeutic regimes based on outcomes of clinical trials even in operable tumors, neoadjuvant hormonotherapy is generally used only in the treatment of locally advanced tumors, particularly in elderly population. There are a number of clinical trials comparing the efficacy of aromatase inhibitors with tamoxifen in the neoadjuvant setting, but there is a lack of comparison studies of neoadjuvant and adjuvant hormonal therapies. In addition to the effectiveness of neoadjuvant hormonotherapy in primary inoperable tumors, this treatment also leads to a reduction of mastectomies compared to breast conservation surgery. It is necessary to specify the optimal length of neoadjuvant hormonotherapy.

Key words

neoadjuvant hormonotherapy, neoadjuvant chemotherapy, estrogen receptor, progesteron receptor, breast conserving surgery, early breast carcinoma